| HS Code | 749351 |
| Product Name | Huangmalian Powder Veterinary Grade API |
| Active Ingredient | Huangmalian |
| Physical Form | Fine free-flowing powder |
| Color | Yellow to brown-yellow |
| Solubility | Sparingly soluble in water; soluble in dilute alcohol |
| Particle Size | At least 95% passing through 80 mesh |
| Storage Conditions | Sealed container, cool dry place, protected from light |
| Shelf Life | 24 months under recommended storage |
| Applicable Dosage Forms | Tablets, injections, capsules, powders, granules, premix, solutions |
As an accredited Huangmalian Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in 25 kg fiber drums with double polythene liners, sealed airtight for stability and safety of veterinary-grade Huangmalian Powder API. |
| Container Loading (20′ FCL) | 20′ FCL container loading of Huangmalian Powder veterinary API, palletized in sealed drums/bags, secured and documented for safe transport. |
| Shipping | Shipped as a sealed, moisture-resistant veterinary-grade API powder in laminated bags or fiber drums. Temperature-controlled transport recommended, away from sunlight and humidity. Fully labeled with SDS, batch certificate, and export documentation. Compliant with international pharmaceutical shipping regulations for safe, traceable delivery worldwide. |
| Storage | Store in a tightly sealed, original container in a cool, dry, well-ventilated area, protected from light and moisture. Keep away from direct sunlight, heat sources, and incompatible materials. Maintain temperatures between 15–30°C, avoid freezing. Ensure area is clean, inaccessible to children and animals, and separate from foodstuffs. Reference product label for exact conditions. |
| Shelf Life | Shelf life is 24 months if stored sealed in original containers in a cool, dry place. |
In high-throughput broiler and layer integrations where mass medication is administered through nipple drinker lines, Huangmalian powder is formulated as a water-soluble powder rather than as a dry feed additive because the drinking-water route permits short-duration exposure without permanent reformulation of basal rations. Finished sachets are required to meet Ph. Eur. 5.1.4 for non-sterile oral powders, and batch release sampling follows ISO 2859-1:1999 general inspection level II with an AQL of 1.0% for critical defects. The label-claim assay window is 90.0–110.0% using an HPLC-DAD method validated according to VICH GL2. The incorporation range in the dry blend is 20.0–40.0 wt% Huangmalian powder with 60.0–80.0 wt% anhydrous dextrose or lactose carrier, while field dilution is 10.0–30.0 g per 100 L of drinking water, equivalent to 0.010–0.030% w/v. In production, the API and carrier are pre-sieved through a 60-mesh (250 µm) stainless-steel screen, charged into a 500 L double-ribbon blender, and mixed for 20 min at 40 rpm; near-infrared homogeneity probes are used to confirm a coefficient of variation of ≤5.0% before discharge. The powder is filled into laminated aluminum foil sachets under ≤30% relative humidity and heat-sealed at 150°C to prevent moisture ingress. Terminal product formats include 100 g, 500 g, and 1 kg sachets packed in 10 kg high-density polyethylene pails, with long-term stability assigned at 24 months under 25°C/60% RH storage.
Parenteral administration demands removal of insoluble fiber, particle-size control, and sterility assurance beyond the requirements of oral powders. The solution is compounded at 0.5–2.0% w/v of Huangmalian powder in Water for Injections conforming to Ph. Eur. 0169, with 0.1% w/v sodium metabisulfite as antioxidant, 0.5% w/v benzyl alcohol where regulatory permits, and sodium chloride for osmolality adjustment to 280–320 mOsm/kg. The pH is adjusted to 5.5–6.0 with 0.1 M hydrochloric acid or sodium hydroxide because higher pH conditions accelerate oxidative darkening of the herbal extract fraction. The manufacturing sequence uses a 316L stainless-steel jacketed vessel with nitrogen overlay, dissolving at 45°C for 30 min, followed by addition of 0.2% w/v activated carbon, stirring for 15 min, and sequential filtration through 0.45 µm and 0.22 µm polyvinylidene fluoride membranes. Terminal sterilization is carried out at 121°C for 15 min in a saturated-steam autoclave validated according to Ph. Eur. 5.1.1, with sterility confirmed by direct inoculation Ph. Eur. 2.6.1 and bacterial endotoxin content controlled to ≤0.50 EU/mg per Ph. Eur. 2.6.14. Filling is performed in Grade A laminar flow over a Grade B background into Type I borosilicate glass vials sealed with chlorobutyl rubber stoppers. Terminal presentations are 10 mL, 50 mL, and 100 mL vials for intramuscular or subcutaneous administration in swine and cattle.
Oral granules for weaned piglets place the API in a solid-dose form that can be top-dressed or mixed into starter feed, but the key process conflict is the reduced aqueous solubility of the API when combined with low-pH binder systems such as citric acid-adipic acid systems. The granule formula includes 5.0–15.0 wt% Huangmalian powder, 2.0–5.0 wt% low-substituted hydroxypropyl cellulose as binder-disintegrant, 0.5–1.0 wt% colloidal silicon dioxide, and lactose monohydrate to 100%. Wet granulation is performed in a 250 L high-shear granulator at an impeller speed of 200 rpm and chopper speed of 1500 rpm, using 10% w/w pregelatinized starch paste as the binding liquid at a binder-to-powder ratio of 0.8:1. The wet mass is extruded through a 1.0 mm screen and dried in a fluid-bed dryer at 55°C for 25–35 min to a final moisture content of ≤3.0%, measured by loss-on-drying at 105°C. Dried granules are sieved through 20-mesh and 40-mesh screens; undersize and oversize fractions are dry-milled and re-blended to maintain content uniformity. Non-sterile granular products are governed by Ph. Eur. 5.1.4 with total aerobic microbial count of ≤10³ CFU/g, total yeast and mould count of ≤10² CFU/g, and absence of Escherichia coli in 1 g. Dissolution testing in 900 mL simulated gastric fluid pH 1.2 at 50 rpm using Ph. Eur. 2.9.3 apparatus 2 requires ≥80% release within 30 min for batch release. Published data for this specific extract-matrix interaction is limited, so the dissolution acceptance criterion is tied to the reference batch fingerprint rather than an absolute pharmacopeial biowaiver. Terminal products are 100 g, 500 g, and 1 kg high-density polyethylene jars containing desiccant sachets.
Feed-mill production schedules for medicated premix intermediates treat the API as a low-inclusion active, requiring stepwise geometric dilution before it can be blended into final feed at the commercial mill or farm. In this scenario, the first compliance boundary is Commission Regulation (EC) No 183/2005 on feed hygiene and the parallel GMP+ Feed Certification scheme for feed additives; analytical traceability is maintained under ISO 6497:2002 for sampling of compound feed, and carryover validation is performed according to the homogenate method in EU Regulation (EC) No 1831/2003 Annex IV. The concentrated premix incorporates 1.0–5.0% w/w Huangmalian powder on a calcium carbonate or rice-hull carrier. The carrier is pre-dried to ≤8.0% moisture and milled through a 0.5 mm screen before blending. Manufacturing proceeds by 5:1 geometric dilution: the API is first mixed with 5.0 kg of carrier in a 20 L V-blender for 10 min, then that pre-blend is added to 25.0 kg of carrier in a 100 L V-blender for 15 min, and the final batch is blended in a 1000 L horizontal ribbon mixer for 25 min at 60% nominal capacity. Homogeneity samples are collected from 10 positions using a stratified sampling plan, and the API assay CV must be ≤5.0%. Final concentrated premixes are packed in 5 kg and 25 kg woven polypropylene bags with inner polyethylene liners; at terminal feed use, the concentrated premix is diluted to deliver 200–500 g/tonne of API in complete feed, equivalent to 0.02–0.05% final feed inclusion.
| Dosage form | Governing standard / method | Critical test parameter | Acceptance threshold |
|---|---|---|---|
| Water-soluble powder | Ph. Eur. 5.1.4; VICH GL2 | TAMC; assay | ≤10³ CFU/g; 90.0–110.0% |
| Injectable solution | Ph. Eur. 5.1.1; 2.6.1; 2.6.14 | Sterility; endotoxins | No growth; ≤0.50 EU/mg |
| Oral granules | Ph. Eur. 5.1.4; 2.9.3 | TAMC; dissolution | ≤10³ CFU/g; ≥80% in 30 min |
| Feed premix | EC 183/2005; ISO 6497:2002 | Assay CV; moisture | ≤5.0%; ≤8.0% |
| Tablet/capsule | Ph. Eur. 2.9.1; 2.9.3; VICH GL2 | Disintegration; dissolution; assay | ≤15 min; ≥75% in 45 min; 95.0–105.0% |
| Lyophilized powder | Ph. Eur. 2.6.1; 2.6.14; 2.5.12 | Sterility; endotoxins; moisture | No growth; ≤0.50 EU/mg; ≤1.0% |
Companion animal dose forms require tighter unit-dose accuracy than mass-medication powders, and direct compression is selected only when the particle-size distribution of Huangmalian powder permits acceptable flow without prior wet massing. The tablet core formula contains 20.0–40.0 wt% Huangmalian powder, 45.0–60.0 wt% microcrystalline cellulose PH102, 5.0 wt% crospovidone, 1.0 wt% colloidal silicon dioxide, and 0.5 wt% magnesium stearate. Before compression, the blend is processed through dry granulation by roller compaction at 6.0–8.0 kN/cm roll force and granule size 1.0–1.5 mm, because the API fraction contains a residual fine fraction that otherwise segregates on the tablet press. Compression is executed on a 12-station rotary press with 10 mm round tooling, applying main compression force of 8.0–12.0 kN to achieve tablet hardness of 60–80 N and friability ≤0.8% per Ph. Eur. 2.9.7. The tablets are tested to Ph. Eur. 2.9.1 for disintegration in water at 37±2°C with an acceptance limit of ≤15 min, uniformity of mass per Ph. Eur. 2.9.5, and dissolution per Ph. Eur. 2.9.3 with ≥75% release in 45 min in 900 mL phosphate buffer pH 6.8. Finished solid-dose presentations are 50 mg and 100 mg film-coated tablets in PVC/PVDC blisters, and HPMC capsules filled with 100 mg or 250 mg API-equivalent blend.
Where reconstitution is required for injectable administration but the API exhibits inadequate solution stability over a full shelf-life in aqueous form, lyophilized powder offers an alternative sterile presentation. The pre-lyophilization solution is prepared by dissolving 50.0–80.0 mg/mL Huangmalian powder in Water for Injections with 4.0–6.0% w/v D-mannitol and 0.5–1.0% w/v sucrose as cryoprotectants; the solution is filtered through 0.22 µm polyvinylidene fluoride membrane and filled as 2.0 mL per 6R Type I glass vial. The lyophilization cycle uses a shelf-freezing step at -40°C for 4 h, primary drying at -20°C shelf temperature and 0.10 mbar chamber pressure for 24 h, and secondary drying at 25°C for 8 h, followed by vacuum stoppering under nitrogen. Sterility is confirmed by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14 with a limit of ≤0.50 EU/mg, residual moisture by Karl Fischer titration according to Ph. Eur. 2.5.12 with ≤1.0%, and reconstitution time in 1 mL Water for Injections is ≤20 s. Terminal presentations are 500 mg and 1 g sterile powder per vial, intended for reconstitution immediately prior to intramuscular or subcutaneous injection.
Competitive Huangmalian Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Huangmalian Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is released as a non-sterile active pharmaceutical ingredient intended for further processing into multiple veterinary dosage forms. The product is designated as a single multi-route grade, not separate oral and injectable grades, with route-specific acceptance criteria added to the certificate of analysis when a batch is allocated to sterile manufacturing. The powder is not intended for direct administration without formulation and release testing. Its usage spans tablet compression, capsule filling, dry powder and granule filling, feed premix manufacture, oral solution compounding, and injectable solution preparation after depyrogenation and sterilisation. The material is differentiated from commodity milled APIs by the simultaneous control of solid-state identity, particle size distribution, residual solvents, elemental impurities, microbial enumeration, and bacterial endotoxin.
Solid-state identity is confirmed by X-ray powder diffraction against the approved reference diffractogram; differential scanning calorimetry is performed at 10°C/min under nitrogen purge to detect polymorphic contamination when a melting endotherm is present. The certificate of analysis reports d10, d50, and d90 from laser diffraction by USP <429>, not a nominal sieve cut. Bulk density and tapped density are determined by USP <616>; these values govern capsule fill weight, die fill consistency, and premix blending behaviour. Loss on drying is tested by USP <731>; if in-process moisture exceeds the compendial limit or ambient relative humidity rises above 60% RH during tablet production, the powder is pre-dried before direct compression. Residue on ignition is controlled by USP <281>. Elemental impurities are assessed according to ICH Q3D and USP <232>; residual solvents are assessed by headspace gas chromatography according to ICH Q3C and USP <467>. Related substances and assay are measured by high-performance liquid chromatography under USP <621>, with specified impurities reported by relative retention time and response factor. Microbial enumeration is performed by USP <61> and specified organisms by USP <62>. Bacterial endotoxin is tested by USP <85> or Ph. Eur. 2.6.14 when the lot is designated for parenteral use. For solution dosage forms, pH is determined by USP <791> and visual clarity is checked at the standard compounding concentration because pH shift can alter solubility and finished solution stability.
| Dosage form | Critical API attribute | Test method | Primary process risk |
|---|---|---|---|
| Tablets | Particle size distribution, bulk/tapped density, loss on drying | USP <429>, USP <616>, USP <731> | Die fill fluctuation, capping, lamination |
| Injections | Bacterial endotoxin, subvisible particulate matter, pH | USP <85>, USP <788>, USP <791> | Pyrogen carryover, precipitation, particulate contamination |
| Capsules | Bulk density, tapped density, particle size distribution | USP <616>, USP <429> | Fill weight drift, plugging, shell closure defects |
| Powders / granules | Loss on drying, particle size distribution, bulk density | USP <731>, USP <429>, USP <616> | Segregation, clumping, poor flow |
| Premix | Particle size distribution, bulk density, loss on drying | USP <811>, USP <616>, USP <731> | Carryover, electrostatic dust, silo segregation |
| Solutions | pH, clarity, related substances | USP <791>, USP <621> | Hydrolysis, incomplete dissolution, visible particulate matter |
The main process conflict is between the particle size envelope preferred for rapid dissolution and the particle size envelope preferred for direct compression die fill. Jet-milled material may dissolve quickly but can exhibit poor flow and high dust; coarse milled material may flow well but dissolve slowly. The powder is controlled by d10, d50, and d90 to allow formulation scientists to select the appropriate particle size for each dosage route. Batch-to-batch variance is assessed by comparing these three values across a minimum of three consecutive lots.
For dry blend and direct compression processes, the powder is first characterised for flow function coefficient, bulk density, and particle size spread. On rotary tablet presses equipped with forced feeders, a wide d10–d90 spread increases the risk of hopper segregation and die fill fluctuation. Production lines handling similar multi-route APIs record weight variability when the powder is transferred directly from drums to the feed hopper without a screening step; the powder is therefore screened through a 0.5 mm conical sieve before dry blending when agglomerates are present. Tablet formulations are evaluated for compactibility, capping tendency, and ejection force at a minimum of three compression forces. Finished tablets are tested for dissolution by USP <711> and for content uniformity by USP <905>. Capsule filling on dosator or tamping pin machines is controlled by setting fill weight against tapped density rather than bulk density alone; lot-to-lot tapped density variation above the specification range can produce fill weight drift and closure defects. Published data for this specific configuration is limited; therefore, compaction profiles and capsule fill parameters are generated for each formulation batch.
Powder and granule filling for sachets and unit-dose packages uses volumetric or auger fillers. The fill weight is controlled by the tapped density and flow function coefficient; materials with poor flow can produce underfilled units and dust accumulation on sealing jaws. Granules are screened to a narrow particle size cut to avoid density stratification during hopper discharge. The powder is not dried beyond the point where the moisture content falls below the equilibrium moisture because an overly dry powder can generate static charge and reduce the precision of auger filling.
Wet granulation modifies the compaction behaviour of the API by changing particle size distribution, density, and residual moisture, even when the binder level is unchanged. In high-shear wet granulation, impeller speed and water addition rate determine granule size distribution; overgranulation can shift the d50 upward and reduce the compactible fraction, while undergranulation leaves a higher proportion of ungranulated fines that may segregate during compression. Fluid-bed drying is preferred when the API is sensitive to residual moisture. The drying endpoint is controlled by loss on drying rather than by fixed time alone, because air volume and inlet temperature interact with the wet mass surface area. A twin-screw continuous granulator with L/D 20:1 may be used as an alternative to high-shear batch equipment; the screw configuration and liquid-to-solid ratio must be optimised because a high liquid feed can produce dense granules with lower porosity and slower dissolution. Dissolution of granules is checked by USP <711> because granule porosity and binder distribution can slow release if the wet mass is overworked. For capsules, wet granulation is used only when direct filling shows unacceptable weight variability; the wet granulated material is milled to a defined d50 range and blended with glidant before encapsulation. Granules for sachet dosing are dried to a lower residual moisture than tablet granules because hydrolysis risk increases with free moisture. This process difference is relevant to the product because it is not restricted to a single granulation route but requires route-specific moisture and particle size targets.
In medicated feed and premix operations, carryover and segregation rather than dissolution become the primary process risk. The API is incorporated into a carrier premix before addition to complete feed; the premix is mixed in horizontal ribbon mixers with coefficient-of-variation targets verified by sampling at multiple points. The particle size distribution of the API influences dust formation and electrostatic adhesion; a powder with excessive fines can adhere to mixer walls and pneumatic conveying lines, reducing assay recovery in the final feed. The powder is therefore specified with a controlled d10 and dustiness parameter when used in premix applications. Bulk density is matched to common carriers such as corncob meal or rice hulls to reduce segregation; if the density difference is too high, the API can stratify during bin discharge. Moisture is controlled because the premix may be stored in unheated warehouses; free moisture above the specification can accelerate microbial growth and cause bridging in silos. The same active ingredient can be formulated into oral solutions and drinking water products, where solubility, pH, and stability in hard water must be evaluated separately. Because published data for this specific configuration is limited, site-specific mix recovery studies and cleanout validation are required before commercial feed production.
During aqueous solution compounding, the API is dissolved in purified water or buffered vehicles; the dissolution profile is checked at target concentration and at lower concentration for drinking water. If the solution is exposed to hard water, divalent cations can compete with counterions and alter saturation solubility. The solution is compounded at pH ranges specified by the master formula; outside these ranges the API may precipitate or undergo hydrolysis. Purified water is preheated only if the formulation development batch confirms temperature stability. The solution is filtered through a clarifying filter before filling oral solution containers; if the product is a drinking water medication, the in-use dilution must be verified at farm water pH and temperature. Because published data for this specific configuration is limited, solution stability studies are performed in each final container.
The injection route introduces the most restrictive quality requirements. The API is not sterile at release but must meet the bacterial endotoxin limit and particulate burden specified for parenteral use. For terminal sterilisation by moist heat, the formulated solution is filled into sealed containers and exposed to an autoclave cycle selected to achieve a sterility assurance level of 10⁻⁶ according to ISO 17665-1. The chemical stability of Huangmalian Powder under a given autoclave cycle must be confirmed by forced degradation studies because published data for this specific configuration is limited. Temperature-sensitive solutions may instead be processed by membrane filtration using 0.22 μm filters and aseptic filling, provided the drug substance has been depyrogenated and the solution passes bacterial retention validation. Subvisible particulate matter in the final injection is controlled by USP <788>; pH is controlled by USP <791>; endotoxin is tested by USP <85> or Ph. Eur. 2.6.14. The powder must dissolve completely at the target concentration without the use of cosolvents that exceed the veterinary formulation safety margin. If the solution is intended for multi-dose vials, antimicrobial preservative efficacy must be demonstrated, and the compatibility of the preservative with the API must be established because incompatibility can alter the preservative assay or produce visible precipitation. The difference from oral-grade APIs is that the same lot can be used for injections only when the endotoxin test is included and the particle size profile supports rapid reconstitution without undissolved drug substance.
Compared with commodity milled APIs that are released only on assay and drying loss, Huangmalian Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is differentiated by the simultaneous control of particle size distribution, endotoxin, residual solvents, elemental impurities, and solid-state identity on the same certificate of analysis. This reduces the need for separate oral and parenteral grades and allows the same API lot to be evaluated for multiple dosage forms after route-specific testing. The main operational limitation is that the powder is not excipient-free and may require screening, drying, or granulation depending on ambient humidity and downstream equipment. It is incompatible with strong oxidising agents and should not be pre-blended with amine-based additives unless compatibility studies are available. The material should be stored in tightly closed containers at controlled room temperature; repeated opening in high-humidity environments above 60% RH may require re-drying. These boundaries do not diminish the multi-route utility but define the process conditions under which the API can be converted into tablets, injections, capsules, powders, granules, premix, or solutions.
